Skip to content
Screener

Total Liabilities at other companies

Arvinas logo
ArvinasARVN
$260.7M-23.5%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$136.19M-14.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$203.88M+123%
Septerna, Inc. logo
Septerna, Inc.SEPN
$191.23M+467%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$48.4M-14.8%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$37.86M-7.2%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemMay 31,2026November 30,2025
Total current liabilities72,02086,471
Operating lease liabilities, net of current portion54,92252,906
Deferred revenue, net of current portion5,97110,011
Total liabilities132,913149,388
Commitments and contingencies (Note 6)
Stockholdersʼ equity:
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2026 and November 30, 2025; no shares issued and outstanding as of May 31, 2026 and November 30, 2025
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2026 and November 30, 2025; 103,701,511 and 101,807,484 shares issued and outstanding as of May 31, 2026 and November 30, 2025, respectively104102

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s total liabilities?
Nurix Therapeutics, Inc. (NRIX) reported total liabilities of $132.91M in Q1 2026.
How has Nurix Therapeutics, Inc.'s total liabilities changed year-over-year?
Nurix Therapeutics, Inc.'s total liabilities decreased by 7.7% year-over-year, from $143.95M to $132.91M.
What is the long-term trend for Nurix Therapeutics, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s total liabilities has grown at a 7.1% compound annual growth rate (CAGR), from $106.07M to $149.39M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Nurix Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude